Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina

G Montalescot1, G Drobinski, J Maclouf

  • 1Department of Cardiology, Hôpital Pitié-Salpétrière, Paris, France.

Circulation
|November 1, 1991
PubMed

Insights

Patients with stable angina show increased thromboxane production during ischemia, but complement system activation is not observed. This suggests thromboxane, not complement, plays a role in angina-related myocardial ischemia.

Area of Science:

  • Cardiology
  • Biochemistry
  • Immunology

Background:

  • The complement system and arachidonic acid metabolites are implicated in myocardial ischemia.
  • Experimental data suggests C5a may contribute to thromboxane production.

Purpose of the Study:

  • To investigate C5a and thromboxane production during brief myocardial ischemia in stable angina patients.
  • To determine the role of complement activation and platelet aggregation in ischemia-induced thromboxane release.

Main Methods:

  • Assessed C5a and thromboxane B2 levels in coronary sinus blood during atrial pacing or percutaneous transluminal coronary angioplasty.
  • Measured urinary thromboxane and prostacyclin metabolites before and after exercise testing.
  • Monitored ST segment changes and lactate extraction to assess ischemia severity.

Main Results:

  • Pacing-induced ischemia increased coronary sinus thromboxane B2 levels, correlating with lactate extraction changes.
  • No significant increase in C5a, C3a, or C5b-9 was detected during ischemia.
  • Patients with stable angina exhibited higher baseline urinary thromboxane metabolites, indicating chronic increased synthesis.

Conclusions:

  • Thromboxane is acutely released during pacing-induced myocardial ischemia in stable angina, independent of significant platelet aggregation.
  • Complement system activation does not appear to be involved in brief ischemic episodes in stable angina.
  • Chronic elevation of thromboxane synthesis is present in patients with stable angina.
Abstract

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Angina I: Introduction01:30

Angina I: Introduction

Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...